Could a vaccine slow Parkinson's? early trial tests UB-312
NCT ID NCT05634876
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tested a vaccine called UB-312 in 8 people with Parkinson's disease or multiple system atrophy. The vaccine is designed to train the immune system to attack abnormal clumps of a protein called alpha-synuclein, which are linked to these brain disorders. The main goals were to check safety and see if the vaccine triggers an immune response in the blood and spinal fluid.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
UB-312 vaccine (synthetic peptide immunogen)
What this could lead to
If successful, this could lead to a vaccine-like treatment that helps the immune system target and clear harmful protein clumps in the brain, potentially slowing disease progression.
What could go wrong
This is a very early Phase 1 trial with only 8 participants, so safety and immune response are the main focus. It is too soon to know if it will work in people, and vaccines for brain diseases have historically been challenging.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PARKINSON DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
NYU Langone Health
New York, New York, 10016, United States